Pals, et al. 1971, Circ. Res. 29:673-681. "Role of the Pressor Action . . . ". |
Zatz, et al. 1985, Proc. Nat. Acad. Sci. 82:5963-5967. "Predominance. . . ". |
Anderson, et al. 1985, J. Clin. Invest. 76:612-619, "Control of . . . ". |
Anderson & Brenner Hypertension: Pathophysiology, Diagnosis & Management Chapt. 72: pp. 1163-1176 (1990). |
Wong, et al., Pharmacol. Exp. Ther., 215:104, 1980. |
Dunn, Hospital Practice, 19:99, 1984. |
Dzau, et al., N. Eng. J. Med., 310:347, 1984. |
Lindgren, et al., Eur. J. Pharmacol., 135:383, 1987. |
Zatz, et al., Kidney International, vol. 31, Suppl. 20, pp. S-123-129 (1987). |
Schmidt et al., J. Cardiovascular Pharmacology, vol. 8, pp. S100-105 (1986). |
Wong et al., Life Sciences, 27:1291-1297 (1980). |
Anderson et al., Hypertension: Pathophysiology, Diagnosis, and Management, Chapter 73, pp. 1163-1176 (1990). |
Anderson et al., Hypertension: Pathophysiology, Diagnosis, and Management, Chapter 104, pp. 1677-1687 (1990). |
Torii, H., Takeda Kenkyushoho, 41, No. 3/4, 180-191, (1982). |
Streeten et al., Handbook of Hypertension, vol. 5, pp. 246-247, (1984). |
Keeton, T. K. et al., Pharmacol. Rev., vol. 31, pp. 81-227, (1981). |
Weinberger, M. H. et al., Medical Clinics N. America, vol. 71, (1987). |
Dunn, M. J., Hospital Practice, vol. 19, pp. 99-113 (1984). |
Satoh et al., Circ. Res., 36/37 (Suppl. I):I-89 to 1-96 (1975). |
Blasingham et al., Am. J. Physiol., vol. 2339, F360, (1980). |
Wong et al., J. Pharmacol. Exp. Therm., vol. 219, pp. 104-109 (1980). |
Raij et al., Journal of Hypertension Supplement, vol. 7, Suppl. 7, pp. S33-S37 (Sep. 1989). |
Abdulkader et al., Brazilian Journal of Medical and Biological Research, 21 (2):233-239 (1988). |
Magnusson et al., Kidney International Supplement 16, vol. 24, pp. S324-S326 (Dec. 1983). |
Huland et al., Transplantation, 36(2):139-142 (Aug. 1983). |
Mento et al., J. Cardiovascular Pharmacol., 8(4):670-675 (1986). |
MacDonald et al., Kidney International, 31 (S20):S148-S153 (1987). |
Anderson et al,, Am. J. Hypertens. 4(5): 11a-12A (1991). |
Lafayette et al., Am. Soc. Nephrology, 23d. Ann. Mtg. (Dec. 2-5, 1990). |
Hutchinson et al., Clinical Research, vol. 539, No. 2, p. 358A (1991). |
H. Torii, Takeda Kenkyushoho, 40, No. 3/4, 180-191 (1982). |
Streeten and Anderson, Handbook of Hypertension, vol. 5, Clinical Pharmacology of Antihypertensive Drugs, A. E. Doyle (Editor), Elsevier Science Publishers B. V., p. 246 (1984). |
Satoh, et al., Cir. Res. 36/37 & Suppl. I):I-89, 1975. |
Blasingham et al., Am. J. Physiol. 239:F360, 1980. |
Wong et al., Abstract No. 30, Hypertension, p. 340. vol. 12, No. 3, Sep. 1988 High Blood Pressure Council Mtg., San Francisco, Calif., Sep. 28-Oct. 1, 1988, "X-6803 Methyl 2-N-Butyl-1-(4-(2-Carboxybenzamido) Benzyl-4-Chloroimidazole-5-Acetate, Sodium Salt): A Novel Nonpeptide Angiotension II Receptor Antagonist". |
Chiu et al., Abstract No. 118.11, The Pharmacologist, vol. 30, p. A165, 1988, for ASPET mtg., Montreal, Canada, Oct. 9-13, 1988: "Nonpeptide Angiotensin II (AII) Receptor Antagonists: Structure Function Studies". |
Wong et al., Nonpeptide Angiotensin II Receptor Antognists. I. Pharmacological Characterization of 2-n-Butyl-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307), "J. Pharmacology and Experimental Therapeutics, "vol. 247, No. 1, pp. 1-7. |